



Exam Initials		Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
			4220653	09-02-1980	Vivino			
			4698327	10-06-1987	Nagarajan			
			5512549	04-30-1996	Chen et al.			
			5432156	07-11-1995	Matsuno			
			5858975	01-12-1999	Yano			
			6268343	07-31-2001	Knudsen			
			6458924	10-01-2002	Knudsen			
			6583111	06-24-2003	DiMarchi et al.			
			6586403	07-01-2003	Mathison			
			6608098	08-19-2003	Nagase et al.			
			7166575	06-17-2004	Quay			
			7459432	12-02-2008	Michael Cowley et al.			

Exam Initials		Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
			20010011071	08-02-2001	Knudsen			
			20010046956	11-29-2001	Hadcock			
			20020156010	10-24-2002	Lustig			
			20040018975	01-29-2004	DiMarchi et al.			
			20050070469	03-31-2005	Bloom			
			20050176630	08-11-2005	Michael Cowley et al.			
			20050176643	08-11-2005	Bridon et al.			
			20060014678	01-19-2006	Michael Cowley et al.			
			20060171920	08-03-2006	Shechter			
			20060189522	08-24-2006	Bloom et al.			
			20080064636	03-13-2008	Bloom et al.			
			20090181885	07-16-2009	Stephen Robert Bloom			

		20090209461	08-20-2009	Imperial Innovations Limited and Oregon Health			
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes	No
		CA 2431800	Amylin Pharmaceuticals, Inc.		06-20-2002		
		CN 1490333	Biotech Co. Ltd. Beijing		04-21-2004	X	
		EP 0619332	Kuraray Co. Ltd.		10-12-1994		
		EP 0708179	Lilly Co Eli		04-24-1996		
		EP 0795562	Kyowa Hakko Kogyo Co. Ltd.		09-17-1997		
		EP 0920864	Pfizer Products Inc.		11-12-1998		
		JP 11-228447	Pfizer Prod Inc. (Abstract)		08-24-1999		
		JP 2001-011095	Novo Nordisk A/S		01-16-2001		
		WO 98/20895	Novo Nordisk A/S		05-22-1998		
		WO 98/30231	Amylin Pharmaceuticals, Inc.		07-16-1998		
		WO 99/39702	Children's Medical Center Corporation		08-12-1999		
		WO 01/87335	Eli Lilly and Company		11-22-2001		
		WO 03/022304	Imp College Innovations		03-20-2003		
		WO 03/026591	Imperial Innovations Limited		04-03-2003		
		WO 03/057235	Imperial Innovations Limited		07-17-2003		
		WO 04/062685	Imperial Innovations Limited		07-29-2004		
		WO 05/035761	Compugen Ltd.		04-21-2005		
		WO 05/118642	Domantis Ltd.		12-15-2005		
		WO 06/082517	Pfizer Prod Inc.		08-10-2006		
		WO 06/095166	IMP Innovations Ltd.		09-14-2006		
		WO 06/134340	Imperial Innovations Limited		12-21-2006		
		WO 07/056362	Indiana University Res and Tec		05-18-2007		
		WO 07/100535	Merck & Co.		09-07-2007		
		WO 07/146038	Human Genome Sciences Inc.		12-21-2007		
		WO 08/003947	Imperial Innovations Limited		01-10-2008		
		WO 08/071972	Imperial Innovations Limited		06-19-2008		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
		P01275 (gi45644939): "Glucagon precursor", GenBank Record dated January 23, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on June 9, 2007, retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=45644939 >, GenBank Accession Number P01275 (gi45644939).	
		P01275 (gi121484): "Glucagon precursor", GenBank Record dated August 20, 2001, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on June 9, 2007, retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?121484 >) JOLD09:43184>, GenBank Accession Number P01275 (gi121484).	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		P01273 (gi1346151): "Glucagon precursor", GenBank Record dated July 10, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on June 9, 2007, retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1346151 >, GenBank Accession Number P01273 (gi1346151).
		P01275: "GLUe_HUMAN", ExpASY [online] Swiss Institute of Bioinformatics (SIB), Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., Bairoch A. ExpASY: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 31:3784-3788(2003), retrieved on May 27, 2005, retrieved from internet using <URL: http://www.au.expasy.org/cgi-bin/sprot-ft-details.pl?P01275@PEPTIDE@53@89 >, ExpASY Accession Number P01275.
		P01272 (gi121479): "Glucagon precursor", GenBank Record dated August 21, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on June 9, 2007, retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=121479 >, GenBank Accession Number P01272 (gi121479).
		P06883 (gi121496): "Glucagon precursor", GenBank Record dated July 10, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on June 9, 2007, retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=121496 >, GenBank Accession Number P06883 (gi121496).
		ALLEN, "Radioimmunoassay of neuropeptide Y", <i>Histochemistry</i> , 80:487 (1984).
		ANDERSON & RASMUSSEN, "Cimetidine and obesity: Conflicting evidence", <i>Intl. J. Obesity</i> 23:550 (1999).
		ASSUNCAO, "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine", <i>Rev. Bras. Psiquiatr</i> 28(4):270-276 (2006).
		BAGGER, "Nasal bioavailability of peptide T in rabbits: Absorption enhancement by sodium glycocholate and glycofurol" <i>Eur. J. Pharm. Sci.</i> 14:69-74 (2001).
		BAYS, "Current and investigational antiobesity agents and obesity therapeutic treatment targets", <i>Obes Res</i> 12(8):1197-211 (2004).
		BOWIE, "Deciphering the message in protein sequences: tolerance to amino acid substitutions", <i>Science</i> , 247:1306-1310 (1990).
		BUSE, "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes", <i>Diabetes Care</i> , 27(11):2628-2635 (2004).
		COHEN, "Oxyntomodulin suppresses appetite and reduces food intake in humans", <i>J. Clin. Endocrinol. Metab.</i> , 88(10):4696-4701 (2003).
		CUMMINGS, "A preprandial rise in plasma ghrelin levels suggest a role in meal initiation in humans", <i>Diabetes</i> , 50:1714-1719 (2001).
		DAKIN, "Oxyntomodulin inhibits food intake in the rat", <i>Endocrinology</i> , 142:4244-4250 (2001).
		DAKIN, "Peripheral oxyntomodulin reduces food intake and body weight gain in rats", <i>Endocrinology</i> , 145:2687-2695 (2004).
		DAKIN, "Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats", <i>Am. J. Physiol. Endocrinol. Metab.</i> , 283:E1173-E1177(2002).
		DAKIN, "Novel Actions of Oxyntomodulin in the Central Nervous System", Dept. of Endocrinology & Metabolism, Imperial College School Medicine, Hammersmith Hospital, Du Cane Road, London. W12

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		ONN, <i>Journal of Endocrinology</i> , March 2000, Volume 164 Supplement (Abstract #181).
		DAKIN, "Novel Actions of Oxyntomodulin in the Central Nervous System", Dept. of Endocrinology & Metabolism, Imperial College School Medicine, Hammersmith Hospital, Du Cane Road, London. W12 ONN. UK presented at 19th Joint Meeting of the British Endocrine Societies, with the European Federation of Endocrine Societies, March 13-16, 2000.
		CAA27627 (gi762941): "unnamed protein product [Homo sapiens]", NCBI Record dated December 3, 2009, (Database Medline [online], Bethesda, MD, USA: US National Library of Medicine (NLM), retrieved from internet using <URL: http://www.ncbi.nlm.nih.gov/protein/762941 , NCBI Accession Number CAA27627 (gi762941).
		ENGLISH, "Food fails to suppress ghrelin levels in obese humans", <i>J Clin Endocrinol Metab</i> , 87:2984-87 (2002).
		ExPasy Proteomics Tools, Compute pI/MW, http://ca.expasy.org/cgi-bin/pi_tool , printed on April 10, 2007.
		GARROW, "Does cimetidine cause weight loss?", <i>BMJ</i> , 306(6885):1084 (1993).
		HOLST, "Enteroglucagon", <i>Ann. Rev. Physiol.</i> , 59:257-271 (1997).
		HOLZ AND HABENER, "Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones", <i>Camp. Biochem. Physiol. Part B</i> 121:177-184 (1998).
		International Preliminary Examination Report dated January 28, 2005 from International Application No. PCT/US02/31944.
		KAWANA, "Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies" <i>Vaccine</i> 19:1496-1502 (2001).
		LEGER, "Identification of CJC-1131-Albumin Bioconjugate as a Stable and Bioactive GLP-1 (7-36) Analog", <i>Bioorganic & Medicinal Chemistry Letters</i> , Oxford, GB, 14:17 (2004) 4395-4398.
		MCNEELY, "Sibutramine. A review of its contribution to the management of obesity", <i>Drugs</i> , 56(6):1093-1124 (1998).
		MESSER, "Vasopressin and Oxytocin", web documents updated 4/3/2000; < http://www.neurosci.pharm.utoledo.edu/MBC33291/vassopressin.htm >
		NATIONAL INSTITUTES OF HEALTH, NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI), "Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health", <i>Obes. Res.</i> , 6 (suppl. 2):51S-209S (1998).
		"OXYNTOMODULIN" Internet Document http://www.glucagon.com/oxyntomodulin.htm > 3/3/01 2 pages, accessed 8/30/06.
		PARKER, Internet Document http://www.futurepundit.com/archives/002946.html > 8/17/05, accessed 8/29/06.
		RASMUSSEN, "Cimetidine suspension as adjuvant to energy restricted diet in treating obesity", <i>BMJ</i> , 306(6885):1093-1096 (1993).
		RUDINGER, In: <i>Peptide Hormones</i> , JA Parsons, Ed. (1976) 1-7.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		SARSON, "Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPP) bypass surgery for morbid obesity", <i>Int. J. Obes.</i> , 5:471-480 (1981).
		SCHJOLDAGER, "Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man", <i>Eur. J. Clin. Invest.</i> , 18(5):499-503 (1988).
		Search Report dated January 23, 2003 from International Application No. PCT/GB02/04082.
		Search Report dated April 9, 2004 from International Application No. PCT/US02/31944.
		Search Report dated September 19, 2003 from International Application No. PCT/GB03/00062.
		Search Report dated March 13, 2007 from International Application No. PCT/GB2006/002155.
		Search Report dated October 19, 2007 from International Application No. PCT/GB2007/002473.
		Search Report dated May 21, 2008 from International Application No. PCT/GB2007/004779.
		SENEL, "Drug permeation enhancement via buccal route: possibilities and limitations", <i>J. Control Release</i> , 72(1-3):133-144 (2001).
		SHERWOOD, "The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily", <i>Endocrine Reviews</i> , 21 (6):619-670 (2000).
		SMILEK, "A Single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 1:88(21):9633-7 (1991).
		STOA-BI RKETVEDT, "Cimetidine reduces weight and improves metabolic control in overweight patients with Type 2 diabetes", <i>International Journal of Obesity Relat. Metab. Disord.</i> , 22(11):1041-1045 (1998).
		STOA-BIRKETVEDT, "Effect of cimetidine suspension on appetite and weight in overweight subjects", <i>BMJ</i> , 306(6885):1091-1093 (1993).
		STOA-BIRKETVEDT, "H2-Receptor antagonist reduces food intake and weight gain in rats by non-gastric acid secretory mechanisms", <i>Scandinavian Physiological Society</i> , 161(4):489-494 (1997).
		TANI, "Oxyntomodulin and related peptides control somatostatin secretion in RIN T3 cells" <i>Biochim. Biophys. Acta</i> 1095:249-254 (1991).
		TZOTSAS, "Use of somatostatin analogues in obesity" <i>Drugs</i> 68: 1963-1973(2008).
		"The Wonders of Weight Loss", <i>American Fitness</i> , Jan/Feb p. 18 (2006).
		UESAKA, "Glucagon-like peptide isolated from the eel intestine: effects on atrial beating", <i>Journal of Experimental Biology</i> , 204:3019-3026 (2001).
		VOET and VOET, <i>Biochemistry</i> , 2nd Edition, pages 235-241 (1995).
		WALAN AND STROM, "Metabolic consequences of reduced gastric acidity", <i>Scand. J. Gastroenterol. Suppl.</i> , 111 :24-30 (1985).
		WILKOSZ, "Transdermal Drug delivery", <i>u.s. Pharmacist</i> , <i>Ajobson publication</i> , 28(4):1-15(2003).
		WOLFE AND MORTON, "Weighing in on bariatric surgery: procedure use, readmission rates, and mortality", <i>JAMA</i> , 294:1960-1963(2005).
		WREN, "Ghrelin enhances appetite and increases food intake in humans", <i>J Clin Endocrinol Metab</i> , 86:5992-5 (2001).

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		WYNNE, "Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial", <i>International Journal of Obesity</i> , 12:1729-1736 (2006).
		WYNNE, "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial", <i>Diabetes</i> , 54: 2390-2395 (2005).

* By the waiver of 37 CFR 1.98(a)(2)(i) a copy of the U.S. Patent A1 is not submitted.

Examiner Signature	/Anand Desai/	Date Considered	11/06/2010
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1008237.1